NCT06922929 2025-04-11
A Multicenter, Open-label, Prospective Phase III Clinical Trial to Evaluate INR101 Injection for PET/CT Imaging in Participants With Suspected Recurrent Prostate Cancer After Radical Treatment
Yunhe Pharmaceutical (Tianjin) Co., Ltd
Phase 3 Not yet recruiting